logo

Clinical Trial Calendar

Share SHARE
Clinical trials are binary speculative events that could make or break biotech stocks. Therefore, knowing the timing of announcement of results for phase I, phase II and phase III clinical studies helps limit risk and maximize profits when trading/investing in biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending clinical trial catalysts. The column "Results Date" refers to the announcement timing of the clinical trial results. But not every time is the schedules and deadlines followed by the companies, because sometimes the results may be announced early if the trial is stopped early due to efficacy or there may be a delay in reporting the results if there are unexpected hurdles in completing the clinical study.
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Mid 2015
Vical Inc.
Efficacy data from phase 1/2 trial of Vaxfectin(R)-formulated therapeutic vaccine
Herpes simplex virus type 2 (HSV-2)
Mid 2015
Fate Therapeutics, Inc
Full data on primary efficacy endpoint from phase II study of PROHEMA
Hematologic malignancies
Mid 2015
Celldex Therapeutics Inc.
First interim analysis of phase III 3 Study of Rindopepimut
Frontline Glioblastoma
Mid 2015
Fate Therapeutics, Inc
Full data on primary efficacy endpoint from phase II study of PROHEMA
Hematologic malignancies in adult subjects undergoing double umbilical cord blood transplantation
Mid 2015
Trevena, Inc.
Data from Phase 2b Study of TRV130
Acute Postoperative Pain
Mid 2015
Alnylam Pharmaceuticals Inc.
Data from Phase 2 study of Patisiran
Familial amyloidotic polyneuropathy (FAP)
Mid 2015
Avalanche Biotechnologies, Inc.
1 year follow-up results from Phase 2a trial of AVA-101
wet AMD
Mid 2015
Aquinox Pharmaceuticals, Inc.
Top-line results from Phase 2 trial of AQX-1125
Bladder pain syndrome/interstitial cystitis in females
Mid 2015
Aquinox Pharmaceuticals, Inc.
Top-line results from Phase 2 trial of AQX-1125
Chronic obstructive pulmonary disease exacerbations
Mid 2015
Recro Pharma Inc.
Top-line data from Phase II trial of Dex-IN
Pain following bunionectomy surgery
Mid 2015
Esperion Therapeutics
Top-line results from phase 2 study of ETC-1002
Hypercholesterolemia and hypertension
Mid 2015
Galena Biopharma, Inc.
Top line data from Phase 2a trial of GALE-301
Ovarian and endometrial cancers
Early Summer 2015
Transition Therapeutics Inc.
TTHI, TTH.TO
Top-line data from phase 2 study of ELND005
Treatment for agitation and aggression in patients with Alzheimer’s disease
2H 2015
Pieris Pharmaceuticals Inc
PIRS.OB
Data from Phase I trial of PRS-080
Anemia
Q3 2015
Apricus Biosciences, Inc.
Topline data from Phase 2a proof-of-concept study of RayVa
Scleroderma patients who also suffer from Raynaud's Phenomenon
2H 2015
Intra-Cellular Therapies, Inc.
Topline data from first Phase 3 trial of ITI-007
Schizophrenia.
Q3 2015
Cara Therapeutics Inc.
Top-line efficacy data from phase 2 trial of I.V. CR845
Uremic pruritus
Q3 2015
Vital Therapies, Inc
Topline data from Phase 3 study of VTI-208
Alcohol induced liver decompensation
Q3 2015
Anacor Pharmaceuticals, Inc.
Top-line data from Phase 3 studies of AN2728
Mild-to-moderate atopic dermatitis
Q3 2015
Conatus Pharmaceuticals Inc
Top line results from Phase 2 trial of Emricasan
Portal Hypertension
2H 2015
Galapagos NV
GLPGF.PK
Topline results from phase 1 study of GLPG1837
Cystic fibrosis patients who carry class III/IV mutations
2H 2015
Chimerix, Inc.
Report results from phase III study of Brincidofovir, dubbed SUPPRESS
Prevention of cytomegalovirus (CMV) infection in hematopoietic cell transplant recipients